Gemcitabine and docetaxel in a patient with primary ovarian leiomyosarcoma: a case report and review of literature

Furutake, Yoko; Fukagawa, Tomoyuki; Suga, Yasuko; Nagasawa, Takayuki; Sato, Seiya; Omi, Hideo; Kagabu, Masahiro; Chiba, Atsumi; Shoji, Tadahiro; Takeuchi, Satoshi; Sugai, Tamotsu; Itamochi, Hiroaki; Sugiyama, Toru

doi:10.1007/s13691-017-0309-7

Cited by 9 publications

(26 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tumour marker CA-125 is usually within normal values or mildly increased ( Rasmussen, 1997 , Tanaka et al, 2018 , Kaur, 2014 ). The International Federation of Gynecology and Obstetrics (FIGO) classification and TNM Classification staging system are utilized to determine the appropriate management ( Arslan, 2011 , Tanaka et al, 2018 , Furutake et al, 2017 ). The stage and the size of the tumour and the mitotic index impact the prognosis ( Pankaj et al, 2013 , Bouie, 2005 ), however, as in other gynecological sarcomas, primary ovarian leiomyosarcoma are not routinely graded.…”

Section: Introductionmentioning

confidence: 99%

“…Histologically, primary ovarian leiomyosarcoma is diagnosed based on the presence of eosinophilic spindle-shaped cells with enlarged, variably pleomorphic nuclei, arranged in intersecting fascicles or sheets ( Pankaj et al, 2013 , Furutake et al, 2017 , Kumar Vijaya et al, 2015 , Bodner et al 2003 ). The nuclei have blunted, or truncated ends and the cells have a dense cytoplasm.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical management and outcomes of primary ovarian leiomyosarcoma – Experience from a sarcoma specialist unit

Cojocaru

Gamage

Butler

et al. 2021

Gynecologic Oncology Reports

View full text Add to dashboard Cite

Ovarian sarcomas account for 1% of all ovarian malignancies and amongst these, primary ovarian leiomyosarcoma is the rarest subtype. Primary ovarian leiomyosarcoma has a very poor prognosis, with less than 20% of patients being alive at 5 years. Only a few cases have been published in the literature and there is very limited knowledge on the clinical behaviour and optimal management of these tumours. We have performed a retrospective analysis of a prospectively maintained database to identify all primary ovarian leiomyosarcoma diagnosed and treated at the Royal Marsden NHS Foundation Trust between 1998 and 2020. Sixteen patients were identified from our database and fifteen were eligible for the analysis. Twelve patients presented with localized disease and underwent initial surgery and three patients had metastatic disease at presentation. Recurrence-free survival post-surgery was 16 months. Eight patients received first-line chemotherapy and four patients received second-line chemotherapy. Two patients had indolent metastatic disease and benefited from local therapies only. The median overall survival in the metastatic setting in our cohort was 51 months, which is consistent with previously published cases. Primary ovarian leiomyosarcoma is an extremely rare malignancy with a poor prognosis. This study is the largest case series of primary ovarian leiomyosarcoma published to date, providing clinically important information regarding survival and metastatic rate as well as treatment outcomes in the metastatic setting.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinical management and outcomes of primary ovarian leiomyosarcoma – Experience from a sarcoma specialist unit

Cojocaru

Gamage

Butler

et al. 2021

Gynecologic Oncology Reports

View full text Add to dashboard Cite

show abstract

“…In general, these pulmonary side effects can be variable in clinical presentation, severity, time from chemotherapy initiation, and clinical response to appropriate therapy for lung injury. They can manifest as mild to severe dyspnea, NCPE, DAH, ARDS, and interstitial pneumonitis (IP) [7][8][9][10][11][12]. Our patient, despite appropriate treatment with early steroid therapy, declined clinically and radiographically.…”

Section: Discussionmentioning

confidence: 95%

“…One case report described a patient who developed likely grade 3 pulmonary toxicity while receiving G/D for metastatic primary ovarian LMS. She completely improved with steroid therapy and continued to receive the same chemotherapy regimen with a partial cancer response [12]. In a report of three patients with metastatic urothelial carcinoma treated with G/D, two had at least grade 3 pulmonary toxicity.…”

Section: Discussionmentioning

confidence: 99%

“…The literature reports a range of clinical response to these interventions. Treatment response ranged from significant improvement with resolution of pulmonary toxicity to rapid progression and to respiratory failure and death [8][9][10][11][12][13]. Fenocchio et al described a case of pancreatic adenocarcinoma treated with gemcitabine where the patient developed severe gemcitabine-induced pulmonary toxicity refractory to steroids and other conventional treatments.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Grade 4 Pneumonitis in a Patient Treated with a Combination of Gemcitabine and Docetaxel for Recurrent Leiomyosarcoma of the Uterus

Wang

Rose

Gettle

et al. 2020

Case Reports in Obstetrics and Gynecology

View full text Add to dashboard Cite

Gemcitabine and docetaxel combination chemotherapy is the standard of care for patients with unresectable recurrent or metastatic leiomyosarcoma of the uterus. Although they are generally well-tolerated agents, they can also cause severe and life-threatening pulmonary toxicities. Here, we describe a case of grade 4 pneumonitis due to gemcitabine and docetaxel in a 74-year-old woman with recurrent, metastatic uterine leiomyosarcoma. Despite early recognition of chemotherapy-induced lung injury and early administration of corticosteroid, she developed noncardiogenic pulmonary edema, diffuse alveolar hemorrhage, and acute respiratory distress syndrome. She required multiple intubations and a tracheostomy. Physicians should not only be aware of gemcitabine and docetaxel’s potential to cause life-threatening pulmonary injuries but also recognize the variability in clinical presentations and treatment responses, the radiographic findings of these lung toxicities, and the need for early corticosteroid therapy in these cases.

show abstract

Mesenchymal Tumors, Pathology of the Ovary

Allo

2023

Encyclopedia of Pathology

View full text Add to dashboard Cite

Gemcitabine and docetaxel in a patient with primary ovarian leiomyosarcoma: a case report and review of literature

Cited by 9 publications

References 28 publications

Clinical management and outcomes of primary ovarian leiomyosarcoma – Experience from a sarcoma specialist unit

Clinical management and outcomes of primary ovarian leiomyosarcoma – Experience from a sarcoma specialist unit

Grade 4 Pneumonitis in a Patient Treated with a Combination of Gemcitabine and Docetaxel for Recurrent Leiomyosarcoma of the Uterus

Mesenchymal Tumors, Pathology of the Ovary

Contact Info

Product

Resources

About